Missing periods in replicate designs [RSABE / ABEL]

posted by ElMaestro  – Belgium?, 2019-10-16 15:10  – Posting: # 20693
Views: 1,567

Hi Hötzi,

» I would say:
  • If a subject does not show up or withdraws consent before the first dose, that’s the end of the story.
    »
  • If a subject drops out in later periods, end of the story as well. Why did they come back?
Did you see cases like this? And if yes, do you know why?

Not a definitive answer, but at some CROs they have SOPs in place to the effect of allowing subjects to come back after they have skipped a period , or fractions of one. This, I think, relates originally to FDA's data driven policies. A subject can walkout on her/his own initiative without even stating a reason, that's how GCP works. There is no clause saying she/he can't come back.
I know, this is messy, but that's the way it is in some clinics.

The alternative may be worse, depending on how you look at it: If a subject misses an ambulatory pk-sample ("I forgot", "I sat stuck in a traffic jam", "My parrot suffered an anxiety attack", "Don't you fucking ask me what I did yesterday, it's none of your business", "I had to watch Conchita Wurst win the Grand Prix" etc.) should she/he then be considered completely out?

Le tits now.

Best regards,
ElMaestro

Complete thread:

Activity
 Admin contact
20,258 posts in 4,264 threads, 1,397 registered users;
online 14 (0 registered, 14 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 21:13 CET

You should treat as many patients as possible with the new drugs
while they still have the power to heal.    Armand Trousseau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5